欧盟 - 英文 - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastic agents - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy.cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

美国 - 英文 - NLM (National Library of Medicine)

e.r. squibb & sons, l.l.c. - ipilimumab (unii: 6t8c155666) (ipilimumab - unii:6t8c155666) - ipilimumab 5 mg in 1 ml - yervoy, as a single agent or in combination with nivolumab, is indicated for the treatment of unresectable or metastatic melanoma in adult and pediatric patients 12 years and older. yervoy is indicated for the adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. yervoy, in combination with nivolumab, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (rcc). yervoy, in combination with nivolumab, is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) metastatic colorectal cancer (mcrc) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. this indication is approved under accelerated approval based on overall response rate and duration of response [

以色列 - 英文 - Ministry of Health

medison pharma ltd - cabozantinib as (s) malate - film coated tablets - cabozantinib as (s) malate 20 mg - cabozantinib - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for advanced renal cell carcinoma- as first-line treatment of adult patients with intermediate or poor risk, per imdc criteria.- in adults following prior vascular endothelial growth factor (vegf)-targeted therapy.cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc), in adults with child-pugh class a hepatic impairment who have previously been treated with sorafenib.differentiated thyroid carcinoma (dtc)cabometyx is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (dtc), refractory or not eligible to radioactive iodine (rai) who have progressed during or after prior systemic therapy.

以色列 - 英文 - Ministry of Health

medison pharma ltd - cabozantinib as (s) malate - film coated tablets - cabozantinib as (s) malate 40 mg - cabozantinib - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for advanced renal cell carcinoma- as first-line treatment of adult patients with intermediate or poor risk, per imdc criteria.- in adults following prior vascular endothelial growth factor (vegf)-targeted therapy.cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc), in adults with child-pugh class a hepatic impairment who have previously been treated with sorafenib.differentiated thyroid carcinoma (dtc)cabometyx is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (dtc), refractory or not eligible to radioactive iodine (rai) who have progressed during or after prior systemic therapy.

以色列 - 英文 - Ministry of Health

medison pharma ltd - cabozantinib as (s) malate - film coated tablets - cabozantinib as (s) malate 60 mg - cabozantinib - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for advanced renal cell carcinoma- as first-line treatment of adult patients with intermediate or poor risk, per imdc criteria.- in adults following prior vascular endothelial growth factor (vegf)-targeted therapy.cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc), in adults with child-pugh class a hepatic impairment who have previously been treated with sorafenib.differentiated thyroid carcinoma (dtc)cabometyx is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (dtc), refractory or not eligible to radioactive iodine (rai) who have progressed during or after prior systemic therapy.

美国 - 英文 - NLM (National Library of Medicine)

merck sharp & dohme corp. - fenbendazole (unii: 621bvt9m36) (fenbendazole - unii:621bvt9m36) - fenbendazole 222 mg in 1 g - panacur® granules 22.2% is used for control of the following internal parasites of the families felidae and ursidae . felidae : lions (panthera leo) . for control of ascarids (toxocara cati, toxascaris leonina) , hookworms (ancylostoma spp.) . tigers (panthera tigris) . for control of ascarids (toxocara cati, toxascaris leonina) , hookworms (ancylostoma spp.) . cheetahs (acinonyx jubatus) . for control of ascarids (toxocara cati, toxascaris leonina) . pumas (felis concolor) , panthers (panthera spp.) , leopards (panthera pardus) , jaguars (panthera onca) . for control of ascarids (toxocara cati, toxascaris leonina) , hookworms (ancylostoma spp.) , tapeworms (taenia hydatigena, t. krabbei, t. taeniaeformis) . ursidae : black bears (ursus americanus) . for control of ascarids (baylisascaris transfuga, toxascaris leonina) , hookworms (ancylostoma caninum) , tapeworms (taenia hydatigena, t. krabbei) . polar bears (ursus maritimus) and grizzly bears (ursus horribilis) . for control of ascarids (baylisascaris transfuga, toxascaris leonina) . none known.

加拿大 - 英文 - Health Canada

lundbeck canada inc - memantine hydrochloride - tablet - 10mg - memantine hydrochloride 10mg - miscellaneous central nervous system agents

加拿大 - 英文 - Health Canada

teva canada limited - memantine hydrochloride - tablet - 10mg - memantine hydrochloride 10mg - miscellaneous central nervous system agents

加拿大 - 英文 - Health Canada

pharmascience inc - memantine hydrochloride - tablet - 10mg - memantine hydrochloride 10mg - miscellaneous central nervous system agents

加拿大 - 英文 - Health Canada

teva canada limited - memantine hydrochloride - tablet - 5mg - memantine hydrochloride 5mg - miscellaneous central nervous system agents